Recruiting
Neoplasm malignant
RecruitingA study to test the safety and effects of TLN-372 alone and with other cancer drugs in patients with advanced solid tumors with KRAS gene changes
Registered drugNo placebo
A study to test the safety and effects of TLN-372 alone and with other cancer drugs in patients with advanced solid tumors with KRAS gene changes
Registered drugNo placebo
- Disease:Neoplasm malignant
- Substances:CetuximabItraconazole+2
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Cetuximab